Bruce Turner
Corporate Officer/Principal presso IMMUNOME, INC.
Patrimonio netto: 631 962 $ in data 31/05/2024
Posizioni attive di Bruce Turner
Società | Posizione | Inizio | Fine |
---|---|---|---|
IMMUNOME, INC. | Corporate Officer/Principal | 02/10/2023 | - |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Direttore/Membro del Consiglio | 01/05/2020 | - |
Fondatore | 01/05/2020 | - | |
Xanadu Bio Inc. | Direttore/Membro del Consiglio | 01/07/2021 | - |
Amministratore Delegato | 01/07/2021 | - | |
Presidente | 01/07/2021 | - | |
Segretario Aziendale | 01/07/2021 | - | |
Treasurer | 01/07/2021 | - |
Storia della carriera di Bruce Turner
Precedenti posizioni note di Bruce Turner
Società | Posizione | Inizio | Fine |
---|---|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Direttore Finanziario/CFO | 01/03/2023 | 01/10/2023 |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | Corporate Officer/Principal | 01/01/2017 | 01/01/2021 |
Hoffman-La Roche, Inc. | Corporate Officer/Principal | 01/01/2013 | 01/01/2017 |
Formazione di Bruce Turner
The University of Chicago | Undergraduate Degree |
University of Pennsylvania Medical Center | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Posizioni
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Founder | 2 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
IMMUNOME, INC. | Health Technology |
Aziende private | 5 |
---|---|
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | Finance |
Hoffman-La Roche, Inc. | Health Technology |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Health Technology |
Xanadu Bio Inc. |
- Borsa valori
- Insiders
- Bruce Turner
- Esperienza